Skip to main navigation
NRx Pharmaceuticals, Inc. homepage
  • Our Company
  • Our Therapeutic Focus
    • Bipolar Depression & Suicidality
    • Chronic Pain
    • Post-Traumatic Stress Disorder
  • Our Science
    • NRX-100/NRX-101
    • Our Clinical Approach
    • Mechanism of Action
    • NMDA & 5HT2A Receptors
    • Publications & Breaking News
    • FDA Designations
  • Pipeline
  • Expanded Access and Right to Try
    • NRX-100
    • NRX-101
  • Investor Relations
    • Analyst Coverage
    • Management Answers to Shareholder Questions
    • cUTI Investor FAQs
    • NRX-100 (Ketamine) Investor FAQs
    • SEC Filings
      • Quarterly Reports
      • Section 16 Filings
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Company Info
      • Management Team
      • Board of Directors
      • Contacts
    • Corporate Governance
      • Board Committees
      • Governance Documents
    • Events
    • Investor FAQs
    • Pipeline
    • Press Releases
    • Broadcast / Media
    • Stock Data
      • Stock Quote & Chart
      • Historical Data
  • Presentation
  • Hope Therapeutics
  • Clinical Trials
  • Contact Us
  • Search

Press Releases

More news releases are coming soon.
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
Displaying 51 - 11 of 11

Corporate Presentation

Click here to view our corporate presentation or on the image below
Corporate Presentation
IP Portfolio
View Our Pipeline
Contact NRx Pharmaceuticals
NRx Pharmaceuticals, Inc. logo
  • Home
  • Our Company
  • Our Science
  • Pipeline
  • Corporate Presentation
  • Hope Therapeutics
  • Investor Relations
  • Resources & Patient Stories
  • Careers
  • Contact Us
  • NRx on Facebook (Opens in new tab)
  • NRx on Twitter (Opens in new tab)
  • NRx on Linkedin (Opens in new tab)
  • Forward Looking Statement
  • Privacy Policy
  • Terms of Use

  • © 2026 NRx Pharmaceuticals, Inc.

  • NRx on Facebook (Opens in new tab)
  • NRx on Twitter (Opens in new tab)
  • NRx on Linkedin (Opens in new tab)